Rhythm Pharmaceuticals Inc (RYTM)
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
📈 **POSITIVE** • Low confidence analysis (55%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (77%) **Content type:** Clinical